Alvogen Pharma (India) Private Limited - Due diligence report

A 360° intelligence report on Alvogen Pharma (India) Private Limited: trust score, financial health, credit view, compliance, directors, gro…

2010-04-13 Bangalore, Karnataka Active Unlisted Active Compliant
Share
AP Alvogen Pharma (India) Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Alvogen Pharma (India) Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Alvogen Pharma (India) Private Limited is assessed as Low Risk with a Trust Score of 92/100. Alvogen Pharma (India) Private Limited is an active private limited indian non-government company incorporated in 2010, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Alvogen Pharma (India) Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
DIVYA CHANDU PATEL 01234567 Director 01/04/2018 6 yrs Approved
SARAL THANGAM 01234567 Director 01/04/2018 6 yrs Approved
FJALAR KRISTJANSSON 01234567 Director 01/04/2018 6 yrs Approved
ADITYA NAGARAJ BELLUR 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Lotus Pharmaceuticals Co Ltd
Subsidiaries
1
Group entities
1
Capital events
3 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Lotus Pharmaceuticals Co Ltd Holding Company 74.00%
Norwich Clinical Services Private Limited Subsidiary Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
Operating for 16+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
No critical warning flags detected in the available data.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment90/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
22 Dec 2022
Director ceased
PETAR ANTONOV
31 Mar 2021
Share transfer (FY 2021)
9999.00000000 shares to LOTUS PHARMACEUTICAL CO. LTD
13 Mar 2019
Director ceased
ARNI HARDARSON
Director ceased
KEVIN MICHAEL BAIN
11 Jun 2018
Director ceased
RENAAT JOZEF JANSSEN
13 Dec 2017
Director appointed
ADITYA NAGARAJ BELLUR (Director)
30 Sep 2015
Director ceased
SARAL THANGAM
20 Sep 2014
Director appointed
SARAL THANGAM (Director)
Director ceased
JAVALI SUDHIR PAI
Director ceased
PANGAL RANGANATH NAYAK
24 Jul 2012
Securities allotted
228464.00 Equity Shares - 22.85 Lakh raised
08 Aug 2011
Securities allotted
157044.00 Equity Shares - 15.70 Lakh raised
31 Dec 2010
Director ceased
PADMASREE BALAJI
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Gentrack Software Private Limited U72500PN2021PTC203197 Pune, Maharashtra, India
V. Desai Colors Private Limited U45402GJ2010PTC061531 Vadodara, Gujarat, India
Devi Eye Hospital U85110KA2009PTC051217 Bangalore, Karnataka, India
Infidigit U74999MH2018PTC306969 Goregaon West, Maharashtra, India
Ayu Health U72900KA2019PTC129117 Bangalore, Karnataka, India
Broadway Malyan U74120MH2011FTC222715 Mumbai, Maharashtra, India
Frontline Systems & Services Private Limited U29142TN1999PTC043667 Porur, Tamil Nadu, India
Lhc Asset And Project Managers Private Limited U74999TG2019PTC131530 Hyderabad, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Alvogen Pharma (India) Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Alvogen Pharma (India) Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Alvogen Pharma (India) Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Alvogen Pharma (India) Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Alvogen Pharma (India) Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Alvogen Pharma (India) Private Limited an active company?

Alvogen Pharma (India) Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Alvogen Pharma (India) Private Limited financially healthy?

Alvogen Pharma (India) Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Alvogen Pharma (India) Private Limited?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Alvogen Pharma (India) Private Limited?

The ultimate holding entity is Lotus Pharmaceuticals Co Ltd. 4 active director(s) are on record.

Does Alvogen Pharma (India) Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Alvogen Pharma (India) Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Alvogen Pharma (India) Private Limited?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.